Ruxolitinib inhibits poly (I:C) and IL-13-induced CCL5
production in bronchial epithelial cells: A potential therapeutic agent
for severe eosinophilic
asthma
Running title: RUXOLITINIB INHIBITS CCL5 PRODUCTION IN BRONCHIAL
EPITHELIUM
Mitsuru Sada1, Masato Watanabe1,
Toshiya Inui1, Keitaro Nakamoto1,
Aya Hirata1, Masuo Nakamura1, Kojiro
Honda1, Takeshi Saraya1, Daisuke
Kurai2, Hirokazu Kimura3, Haruyuki
Ishii1 & Hajime Takizawa1
1 Department of Respiratory Medicine, Kyorin
University School of Medicine, Tokyo, Japan
2 Department of General Medicine, Division of
Infectious Diseases, School of Medicine, Kyorin University, Tokyo, Japan
3 Department of Health Science, Graduate School of
Health Science, Gunma Paz University, Gunma, Japan.
Correspondence: Mitsuru SadaPhone: +81(0)-422-47-5511
e-mail:rainbow_orchestra716@yahoo.co.jp
Key Words: CCL5, Eosinophilic asthma, Ruxolitinib, Bronchial epithelium,
IL-13